Product Description
Acetylcysteine inhalation is used along with other treatments to relieve chest congestion due to thick or abnormal mucous secretions in people with lung conditions including asthma, emphysema, bronchitis and cystic fibrosis (an inborn disease that causes problems with breathing, digestion, and reproduction). Acetylcysteine is in a class of medications called mucolytic agents. It works by thinning the mucus in the air passages to make it easier to cough up the mucus and clear the airways.
Mechanisms of Action: GLUR Modulator
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Zambon
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, Italy
Active Clinical Trial Count: 11
Highest Development Phases
Phase 3: Common Cold|Liver Failure|Respiratory Tract Infections
Phase 2: Cocaine-Related Disorders|Cognitive Dysfunction|Deafness|Hearing Loss|Ovarian Cancer
Phase 1: Bronchitis, Chronic|COVID-19|Chronic Cough|Chronic Obstructive Pulmonary Disease|Emphysema
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-000420-34 | P2 |
Active, not recruiting |
Cocaine-Related Disorders |
2030-02-13 |
|
| CRCI | P2 |
Not yet recruiting |
Cognitive Dysfunction|Ovarian Cancer |
2025-12-01 |
|
| 23CT0001 | P3 |
Unknown Status |
Respiratory Tract Infections |
2025-03-31 |
|
| NCT04291209 | P2 |
Recruiting |
Deafness|Hearing Loss |
2024-05-01 |